CareDx Bets on Earnouts to Close a $260 Million Diagnostics Deal

CareDx announced on April 28 that it has agreed to acquire Naveris, a precision oncology diagnostics company, for $160 million in cash plus up to $100 million in revenue-based earnouts. The transaction is small by megadeal standards, but the structure is worth a closer look. It illustrates how buyers and sellers in 2026 are using contingent consideration to close gaps that fixed-price negotiations no longer reliably resolve.

What the Deal Looks Like on Paper

Naveris brings a single, commercially validated product to the transaction: NavDx, a blood-based test that detects tumor-modified viral DNA fragments shed by HPV-driven cancers. The company reported approximately $34 million of revenue in 2025 and roughly $12 million in the first quarter of 2026, with gross margins near 65 percent and a near-breakeven operating result. CareDx is paying $160 million at close, with up to $100 million more contingent on Naveris hitting future revenue milestones. The deal is expected to close in the third quarter of 2026, subject to customary regulatory clearances. Goldman Sachs is acting as financial advisor to CareDx; Fenwick & West is providing legal counsel.

For context, the upfront cash component alone implies a trailing revenue multiple of roughly 4.7x against 2025 results, with the maximum payout pushing the headline multiple closer to 7.6x. Both figures sit comfortably inside the range diagnostics buyers have been paying for assets with strong reimbursement and growth trajectory, but only if Naveris delivers on the second half of the equation.

Why Earnouts Are Doing More Work in 2026

The valuation environment heading into this year has been defined by stubborn buyer-seller spreads. Sellers point to sticky inflation in private market multiples and the strength of recent recurring-revenue diagnostics deals. Buyers point to higher capital costs, tighter due diligence findings, and a longer list of post-close integration risks. Earnouts let the parties agree on price by deferring the part of the disagreement that depends on future performance.

In life sciences specifically, the case for contingent consideration is reinforced by clinical and reimbursement uncertainty. A blood-based diagnostic with an established Medicare pathway, like NavDx, has a credible revenue ramp, but volume growth depends on commercial expansion, payer adoption beyond Medicare, and clinician acceptance in adjacent indications. None of those variables are knowable on signing day. Tying a portion of the price to revenue achievement converts seller optimism into a binding promise rather than a debate.

What Sellers Should Watch in an Earnout Negotiation

If you are on the sell-side and a buyer proposes contingent consideration, the structure deserves more scrutiny than the headline number. The economic value of an earnout is a function of the metric, the measurement period, the threshold for payment, and the buyer's post-close behavior. Each of those elements can be drafted in ways that materially shift expected value.

Revenue-based earnouts, like the one in the CareDx structure, are easier to measure than EBITDA-based earnouts because they are less susceptible to allocation disputes. EBITDA earnouts invite arguments about acquirer overhead, intercompany pricing, and accounting policy choices that can suppress the metric without changing the underlying business. Revenue earnouts have their own risks (channel mix, pricing decisions, bundling with the parent's products) but they tend to litigate less often.

Measurement period also matters. A two-year earnout favors the seller if the business is on a clear ramp, because it limits the exposure to commercial reality reasserting itself. A three- or four-year earnout favors the buyer if growth is expected to flatten. The CareDx and Naveris parties have not publicly disclosed the duration, but the ratio of contingent to upfront ($100 million of $260 million, or roughly 38 percent) is meaningful enough that sellers in any comparable situation should plan for active engagement through the full earnout period.

Buyer Considerations and Integration Discipline

From the buyer's perspective, the most common earnout failure mode is not a dispute over the metric. It is a strategic decision after close that suppresses the relevant number for legitimate business reasons. Reorganizing the sales force, repricing the product, bundling with adjacent offerings, or shifting investment toward a longer-term opportunity can each pull the earnout metric down even when the combined business is more valuable. Acquirers should walk into the deal with an explicit view on which post-close levers they intend to pull during the earnout period and which they will defer.

The covenant package matters here. Strong sellers negotiate operating covenants that constrain the buyer from taking actions that would predictably reduce earnout achievement, including obligations to maintain dedicated sales coverage, fund agreed marketing spend, and avoid product-line decisions that materially divert revenue. The right balance gives the buyer flexibility on long-term strategy while protecting the seller from value erosion during the measurement period.

Diligence Implications

Earnout-heavy structures shift the center of gravity in diligence. Beyond the standard quality-of-earnings work, both sides need a sharper view of the revenue model's operating assumptions: payer mix, average selling price by channel, sales-rep productivity, and contract renewal patterns. The same analysis that supports the headline valuation also feeds the earnout model, so inconsistencies between the two surface uncomfortable questions late in the process.

For Naveris, the diligence narrative likely centered on Medicare reimbursement durability, clinician adoption in HPV-positive head and neck cancer, and the runway for label expansion. Each of those threads carries direct implications for whether the earnout pays in full, in part, or not at all. Sellers preparing for a similar process should expect buyers to model each scenario explicitly and to build the resulting expected-value range into the upfront price.

What This Signals About Diagnostics M&A

The Naveris transaction also says something about where strategic acquirers in diagnostics are willing to spend. CareDx is anchoring its growth in transplant patient management, and the Naveris acquisition extends the company's molecular surveillance capabilities into oncology. Buyers in diagnostics are paying meaningful premiums for assets that combine a defensible reimbursement pathway, a clinical use case with a clear unmet need, and a commercialization team that has already proven the test in market.

For middle-market diagnostics companies considering a sale process in 2026, three signals are worth tracking. First, strategic buyers are willing to pay revenue multiples that compete with software multiples when the asset has an established Medicare pathway. Second, contingent structures will likely feature in any transaction where the revenue ramp is steep but unproven at scale. Third, advisor and legal selection matters: the diligence and structuring sophistication on display in CareDx and Naveris reflects what is now standard in the segment.